Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1311 Paclitaxel/Carboplatin With/Without Bevacizumab in Advanced or Recurrent Cervical Cancer
jRCTs031180007Phase 3Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2015
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of paclitaxel, carboplatin and bevacizumab in Cervical Cancer (CC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Phase II: Response rate and Phase III: Overall survival. Started Oct 2015; status: completed.
02
Drugs
paclitaxelcarboplatinbevacizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCTs031180007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180007.